Nomura Reaffirms “Buy” Rating for Voyager Therapeutics (NASDAQ:VYGR)
Nomura reissued their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report report published on Tuesday morning, AnalystRatings.com reports. Nomura currently has a $37.00 price objective on the stock.
“Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future.”,” Nomura’s analyst wrote.
A number of other research firms have also recently weighed in on VYGR. Wedbush raised their price objective on Voyager Therapeutics from $27.00 to $36.00 and gave the stock an outperform rating in a research report on Tuesday, June 18th. Morgan Stanley raised their price objective on Voyager Therapeutics from $21.00 to $28.00 and gave the stock an equal weight rating in a research report on Friday, July 12th. HC Wainwright reissued a buy rating and issued a $26.00 price objective on shares of Voyager Therapeutics in a research report on Monday, August 12th. Finally, BidaskClub cut Voyager Therapeutics from a hold rating to a sell rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Voyager Therapeutics has an average rating of Buy and an average price target of $27.50.
Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Friday, August 9th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $1.17. The business had revenue of $46.09 million for the quarter, compared to analysts’ expectations of $5.25 million. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. As a group, analysts forecast that Voyager Therapeutics will post -2.44 EPS for the current year.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Voyager Therapeutics by 9.8% in the 2nd quarter. BlackRock Inc. now owns 2,079,554 shares of the company’s stock worth $56,605,000 after purchasing an additional 185,582 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Voyager Therapeutics by 12.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,571,862 shares of the company’s stock worth $42,787,000 after purchasing an additional 180,087 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Voyager Therapeutics by 48.2% in the 2nd quarter. Renaissance Technologies LLC now owns 729,801 shares of the company’s stock worth $19,865,000 after purchasing an additional 237,500 shares in the last quarter. Invesco Ltd. boosted its position in shares of Voyager Therapeutics by 643.6% in the 2nd quarter. Invesco Ltd. now owns 421,155 shares of the company’s stock worth $11,464,000 after purchasing an additional 364,516 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its position in shares of Voyager Therapeutics by 93,030.6% in the 1st quarter. Clearbridge Investments LLC now owns 379,973 shares of the company’s stock worth $7,273,000 after purchasing an additional 379,565 shares in the last quarter. 73.92% of the stock is owned by hedge funds and other institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Featured Story: Moving Average (MA)
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.